Nautilus Biotechnolgy

NAUT

시가총액 US$2.62억

SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2026 before market open on Tuesday, October 27, 2026.

Nautilus Biotechnology is pivoting to a proteoform-focused strategy, prioritizing technically validated, commercially demanded assays over broad-scale proteomics. NAUT's near-term upside hinges on successful execution of the Voyager platform launch and proteoform assay commercialization, with key catalysts expected in 2027. Financially, NAUT maintains a stable burn rate, with $129.2 million in cash providing runway into 2028 and reducing immediate dilution risk.

First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas

NAUT is now prioritizing targeted proteoform assays after Broadscale testing failed to support its prior commercialization roadmap. But their roadmap with Voyager is clearer, although Early Access revenue remains too limited to prove it can turn into recurring sales. Unfortunately, the main risks going forward are still tied to potential execution setbacks, its ongoing cash burn, and a likely capital raise by 2027.

Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript

Nautilus Biotechnology NASDAQ: NAUT said it is shifting a significant share of its research and development resources toward proteoform applications, citing customer interest and a delay in its Broadscale broad-proteome program.

SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Business Highlights Recognized first revenue in the second quarter of 2026, including grant revenue from the Michael J.

SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter 2026 before market open on Tuesday, July 28, 2026. The company's management will webcast a corresponding conference call beginning at 5:30 a.m.

Don't rule out the possibility of rate cuts helping smaller companies in 2026.

Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript